Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

HIV regimens for treatment-naive patients compared

Treatment regimens

Patients received either efavirenz (Sustiva) 600mg plus tenofovir disoproxil (Viread) 300mg and emtricitabine (Emtriva) 200mg once daily, or efavirenz 600mg once daily plus a fixed dose of zidovudine 300mg and lamivudine 150mg twice daily (Combivir).

After comparing two regimens for treatment-naive HIV patients, researchers suggest that a tenofovir-emtricitabine regimen is better than a zidovudine-lamivudine regimen in terms of lowering viral levels and increasing CD4 count (New England Journal of Medicine 2006;354:251).

An open-label study involving 517 patients compared two regimens (see Panel). The primary outcome measure was the proportion of patients with HIV RNA levels of less than 400 copies/ml at week 48.

The researchers found that more patients in the tenofovir-emtricitabine group reached the primary endpoint than in the zidovudine-lamivudine group (84 per cent versus 73 per cent, 95 per cent confidence interval for the difference 4–19; P=0.002). This difference not only indicates that tenofovir-emtricitabine is not inferior to zidovudine-lamivudine but shows a superior response, say the researchers.

They also observed that more patients in the tenofovir-emtricitabine group maintained HIV RNA levels of less than 50 copies/ml (P=0.02). CD4 counts were also higher in this group and adverse events resulting in drug discontinuation were lower.

“These findings have important implications for the choice of an initial nucleoside-analogue backbone in the treatment of such patients,” the researchers conclude.

Citation: The Pharmaceutical Journal URI: 10020835

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.